

Drug resistance interpretation: PR		HIVDB 9.5.1 (2023-11-05)
PI Major Mutations:	None	
PI Accessory Mutations:	None	
PR Other Mutations:	I13V ^{88%} _{cov=33,553} • L19L ^{1: 87%} _{cov=36,105} • P39PS ^{1: 80%} _{cov=42,703} • R41K ^{88%} _{cov=42,472} • L63P ^{81%} _{cov=33,663} • H69Q ^{91%} _{cov=31,805} • V75I ^{91%} _{cov=28,211} • V77I ^{92%} _{cov=27,639} • I93L ^{93%} _{cov=22,143}	
Protease Inhibitors		
atazanavir/r (ATV/r)	Susceptible	
darunavir/r (DRV/r)	Susceptible	
lopinavir/r (LPV/r)	Susceptible	
Mutation scoring: PR		HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT

HIVDB 9.5.1 (2023-11-05)

NRTI Mutations:

NNRTI Mutations:

RT Other Mutations:

M184V93% cov=13,163

A98G99% cov=18,859

K101E96% cov=18,467

V108I96% cov=18,283

Y181C95% cov=12,993

G190A94% cov=13,527

P4T92% cov=21,023

V35T99% cov=19,134

K49R96% cov=29,327

V60I99% cov=20,343

D121Y96% cov=16,177

K122E98% cov=16,136

I135T99% cov=13,946

S162C93% cov=13,274

I167IM1: 73%, M: 20% cov=13,121

D177E98% cov=12,800

V179I95% cov=12,941

T200I94% cov=25,403

Q207E96% cov=12,638

R211K95% cov=12,723

F214L94% cov=15,460

K219H94% cov=16,694

V241L94% cov=20,072

V245K95% cov=18,035

D250E97% cov=18,862

I257L94% cov=20,322

K277R95% cov=21,517

L282C97% cov=21,229

I293V98% cov=24,331

Q334QN1: 81%, N: 17% cov=56

G335D72% cov=57

Nucleoside Reverse Transcriptase Inhibitors

abacavir (ABC)

Low-Level Resistance

zidovudine (AZT)

Susceptible

emtricitabine (FTC)

High-Level Resistance

lamivudine (3TC)

High-Level Resistance

tenofovir (TDF)

Susceptible

Non-nucleoside Reverse Transcriptase Inhibitors

doravirine (DOR)

High-Level Resistance

efavirenz (EFV)

High-Level Resistance

etravirine (ETR)

High-Level Resistance

nevirapine (NVP)

High-Level Resistance

rilpivirine (RPV)

High-Level Resistance

RT comments

NRTI

M184V/I

cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication.

NNRTI

A98G

is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs.

K101E

is a non-polymorphic accessory mutation that confers intermediate resistance to NVP and RPV and low-level reductions in susceptibility to EFV, ETR, and DOR when it occurs with other NNRTI-resistance mutations.

V108I

is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It appears to contribute to reduced susceptibility to most NNRTIs only in combination with other NNRTI-resistance mutations.

Y181C

is a non-polymorphic mutation selected in persons receiving NVP, ETR and RPV. It confers high-level resistance to NVP, intermediate resistance to ETR and RPV, and low-level resistance to EFV. It does not significantly reduce DOR susceptibility.

G190A

is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It does not significantly reduce susceptibility to RPV, ETR, or DOR.

Other

V179I

is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.

K219E/Q/N/R

are accessory TAMS that usually occur in combination with multiple other TAMS. K219W is an uncommon NRTI-selected mutation. K219H is an unusual mutation at this position.

Mutation scoring: RT	HIVDB 9.5.1 (2023-11-05)
----------------------	--------------------------

Drug resistance mutation scores of NRTI:

Download CSV

Rule	ABC	AZT	FTC	3TC	TDF
M184V	15	-10	60	60	-10

Drug resistance mutation scores of NNRTI:

Download CSV



Rule	DOR ↕	EFV ↕	ETR ↕	NVP ↕	RPV ↕
<u>A98G</u>	15	15	10	30	15
<u>A98G + Y181C</u>	5	5	5	5	5
<u>K101E</u>	15	15	15	30	45
<u>K101E + G190A</u>	5	0	5	0	0
<u>V108I</u>	10	10	0	15	0
<u>V108I + Y181C</u>	5	0	0	0	0
<u>Y181C</u>	10	30	30	60	45
<u>Y181C + G190A</u>	10	0	10	0	10
<u>K101E + Y181C</u>	0	5	5	5	0
<u>G190A</u>	0	45	10	60	15
Total	75	125	90	205	135